Athira Sethu
Kochi, 6 April 2026
Aurobindo Pharma Ltd. will be under the spotlight after its board approved an ₹800 crore buyback of equity shares, marking the company’s first repurchase in nearly two years. The buyback, carried out via the tender offer route, will repurchase up to 54.23 lakh shares at a premium price of ₹1,475 each, representing 0.93% of the total equity. Shareholders recorded as of April 16, 2026, will be eligible to participate, continuing the company’s strategy to return value to investors.
Buyback Details
| Parameter | Detail |
| Buyback Amount | ₹800 crore |
| Shares to be Repurchased | 54,23,728 shares |
| Face Value per Share | ₹1 |
| Buyback Price per Share | ₹1,475 |
| Premium over Last Close | 10% |
| Percentage of Total Equity | 0.93% |
| Buyback Route | Tender Offer |
Record Date for Eligibility
| Event | Date |
| Record Date | April 17, 2026 |
| Eligibility Based on Demat Closing | April 16, 2026 |
Previous Buyback History
| Year | Shares Repurchased | Price per Share (₹) | Total Spend (₹ crore) | Route |
| 2024 | 51.36 lakh | 1,460 | 750 | Tender Offer |
Stock Performance Snapshot
| Metric | Value |
| Last Close (April 3, 2026) | ₹1,336 |
| 52-Week High | ₹1,359.9 |
| One-Month Gain | 8.5% |
